Sharon Mates is Chairman and CEO of Intra-Cellular Therapies, Inc.. Currently has a direct ownership of 1.07 Million shares of ITCI, which is worth approximately $92.2 Million. The most recent transaction as insider was on Jan 18, 2024, when has been sold 67,917 shares (Common Stock) at a price of $65.72 per share, resulting in proceeds of $4,463,505. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 1.07M
0% 3M change
1.91% 12M change
Total Value Held $92.2 Million

Sharon Mates Transaction History

Date Transaction Value Shares Traded Shares Held Form
Jan 18 2024
SELL
Open market or private sale
$4,463,505 $65.72 p/Share
67,917 Reduced 6.07%
1,050,309 Common Stock
Jan 18 2024
BUY
Exercise of conversion of derivative security
$1,145,080 $16.86 p/Share
67,917 Added 5.73%
1,118,226 Common Stock
Jan 17 2024
SELL
Open market or private sale
$3,189,411 $66.33 p/Share
48,084 Reduced 4.38%
1,050,309 Common Stock
Jan 17 2024
BUY
Exercise of conversion of derivative security
$810,696 $16.86 p/Share
48,084 Added 4.19%
1,098,393 Common Stock
Jan 16 2024
SELL
Open market or private sale
$5,058,983 $67.13 p/Share
75,361 Reduced 6.69%
1,050,309 Common Stock
Jan 16 2024
BUY
Exercise of conversion of derivative security
$1,270,586 $16.86 p/Share
75,361 Added 6.27%
1,125,670 Common Stock
Sep 19 2023
SELL
Open market or private sale
$2,405,852 $54.17 p/Share
44,413 Reduced 4.06%
1,050,309 Common Stock
Sep 18 2023
SELL
Open market or private sale
$2,987,801 $53.75 p/Share
55,587 Reduced 4.83%
1,094,722 Common Stock
Mar 13 2023
SELL
Open market or private sale
$916,582 $44.57 p/Share
20,565 Reduced 1.79%
1,130,309 Common Stock
Mar 13 2023
BUY
Exercise of conversion of derivative security
$65,199 $3.26 p/Share
20,000 Added 1.71%
1,150,309 Common Stock
Mar 10 2023
SELL
Open market or private sale
$1,791,515 $42.89 p/Share
41,770 Reduced 3.56%
1,130,309 Common Stock
Mar 10 2023
BUY
Exercise of conversion of derivative security
-
20,565 Added 1.76%
1,150,874 Common Stock
Mar 09 2023
BUY
Grant, award, or other acquisition
-
41,770 Added 3.44%
1,172,079 Common Stock
Feb 24 2023
SELL
Open market or private sale
$1,062,407 $47.03 p/Share
22,590 Reduced 2.01%
1,100,309 Common Stock
Feb 24 2023
BUY
Exercise of conversion of derivative security
$97,800 $3.26 p/Share
30,000 Added 2.59%
1,130,309 Common Stock
Feb 23 2023
BUY
Exercise of conversion of derivative security
-
22,590 Added 1.97%
1,122,899 Common Stock
Feb 21 2023
SELL
Open market or private sale
$1,338,096 $48.05 p/Share
27,848 Reduced 2.47%
1,100,309 Common Stock
Feb 18 2023
BUY
Exercise of conversion of derivative security
-
27,848 Added 2.41%
1,128,157 Common Stock
Dec 13 2022
SELL
Open market or private sale
$1,819,565 $55.0 p/Share
33,083 Reduced 2.92%
1,100,309 Common Stock
Mar 09 2022
BUY
Exercise of conversion of derivative security
$110,547 $2.84 p/Share
38,925 Added 3.32%
1,133,392 Common Stock
Feb 24 2022
SELL
Open market or private sale
$1,166,270 $51.63 p/Share
22,589 Reduced 2.02%
1,094,467 Common Stock
Feb 23 2022
BUY
Exercise of conversion of derivative security
-
22,589 Added 1.98%
1,117,056 Common Stock
Feb 22 2022
SELL
Open market or private sale
$1,541,610 $55.36 p/Share
27,847 Reduced 2.48%
1,094,467 Common Stock
Feb 18 2022
BUY
Exercise of conversion of derivative security
-
27,847 Added 2.42%
1,122,314 Common Stock
Jan 10 2022
SELL
Open market or private sale
$1,712,289 $40.87 p/Share
41,896 Reduced 3.69%
1,094,467 Common Stock
SM

Sharon Mates

Chairman and CEO
New York, NY

Track Institutional and Insider Activities on ITCI

Follow Intra-Cellular Therapies, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells ITCI shares.

Notify only if

Insider Trading

Get notified when an Intra Cellular Therapies, Inc. insider buys or sells ITCI shares.

Notify only if

News

Receive news related to Intra-Cellular Therapies, Inc.

Track Activities on ITCI